US 11,879,014 B2
Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
Anne Goubier, Hertfordshire (GB); Josephine Salimu, Hertfordshire (GB); Kevin Moulder, Hertfordshire (GB); Beatriz Goyenechea Corzo, Hertfordshire (GB); Pascal Merchiers, Hertfordshire (GB); Sergio Quezada, London (GB); Karl Peggs, London (GB); Frederick Arce Vargas, London (GB); and Isabelle Solomon, London (GB)
Assigned to Tusk Therapeutics Ltd., Hertfordshire (GB); and Cancer Research Technology Limited, London (GB)
Appl. No. 16/494,962
Filed by Tusk Therapeutics Ltd., Hertfordshire (GB); and Cancer Research Technology Limited, London (GB)
PCT Filed Mar. 3, 2018, PCT No. PCT/EP2018/056312
§ 371(c)(1), (2) Date Sep. 17, 2019,
PCT Pub. No. WO2018/167104, PCT Pub. Date Sep. 20, 2018.
Claims priority of application No. 17161717 (EP), filed on Mar. 17, 2017; application No. 1710879 (GB), filed on Jul. 6, 2017; and application No. 1714429 (GB), filed on Sep. 7, 2017.
Prior Publication US 2020/0010554 A1, Jan. 9, 2020
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 14/55 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2866 (2013.01) [C07K 14/55 (2013.01); C07K 16/2818 (2013.01); A61K 39/0011 (2013.01); A61K 45/06 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/60 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 16 Claims
 
1. A method of treating cancer in a human subject comprising the step of administering a human IgG1 anti-CD25 antibody to a subject, wherein said subject has a solid tumour, wherein said antibody does not inhibit the binding of Interleukin-2 (IL-2) to CD25.